At the 38th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), 9,000 participants from 100 countries learned about the latest developments in research and care, with 1,700 abstracts presented.
Here, Professor Patrick Vermersch (University of Lille, France) comments on selected highlights from the event, held in Amsterdam, The Netherlands, on 26-28 October 2022. For more from ECTRIMS 2022, see Neurodiem’s daily coverage of the event.
---
RIS: to treat or not to treat?
One of the most interesting events at ECTRIMS 2022 was the “Burning Debate” about radiologically isolated syndrome (RIS) – also the subject of some important new research presented at the conference, including the late-breaking results of the ARISE trial.